Image SmartVestSQL_250The SmartVest SQL, the newest model for Electromed Inc’s SmartVest Airway Clearance System, has been cleared to market by the U.S. Food and Drug Administration.

SQL is an electrically-powered precursor device designed to deliver high frequency chest wall oscillation (HFCWO) to promote airway clearance, improve bronchial drainage, and enhance mucus transport, according to Electromed. HFCWO has been demonstrated to reduce lung infections and reduce health care costs associated with recurrent pneumonias, antibiotic use, and hospital stays.

The device is equipped with a lightweight, soft-fabric garment and features enhanced ramping, an enhanced pause feature and more user-friendly graphics, the company said.

“SQL solidifies Electromed’s innovation leadership by offering a device that is smaller, quieter, and lighter than our previous versions,” said Kathleen Skarvan, CEO for Electromed. “We believe we have the most comfortable and easy-to-use system among leading HFCWO devices, which leads to therapy adherence and better patient outcomes.”

The device is available by physician’s prescription for patients with a wide range of pulmonary-related health conditions, including bronchiectasis, COPD, cystic fibrosis, muscular dystrophy, and cerebral palsy.

SmartVest SQL is expected to be available in the U.S. within the next 60 days, according to Electromed.